{{Rsnum
|rsid=10824792
|Gene=MBL2
|Chromosome=10
|position=54526206
|Orientation=plus
|GMAF=0.4848
|Gene_s=MBL2
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=137
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 17.7 | 49.6 | 32.7
| HCB | 14.7 | 50.0 | 35.3
| JPT | 15.9 | 43.4 | 40.7
| YRI | 74.8 | 24.5 | 0.7
| ASW | 68.4 | 22.8 | 8.8
| CHB | 14.7 | 50.0 | 35.3
| CHD | 11.2 | 61.7 | 27.1
| GIH | 14.9 | 48.5 | 36.6
| LWK | 86.4 | 12.7 | 0.9
| MEX | 10.3 | 39.7 | 50.0
| MKK | 53.2 | 41.7 | 5.1
| TSI | 17.6 | 40.2 | 42.2
| HapMapRevision=28
}}{{PMID Auto
|PMID=23576520
|Title=Genetic Polymorphisms in Host Innate Immune Sensor Genes and the Risk of Nasopharyngeal Carcinoma in North Africa
|OA=1
}}

{{PMID Auto
|PMID=17071626
|Title=The mannose-binding lectin (MBL2) haplotype and breast cancer: an association study in African-American and Caucasian women.
}}

{{PMID Auto
|PMID=17327408
|Title=Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.
|OA=1
}}

{{PMID Auto
|PMID=18396467
|Title=Genetic variation and haplotype structures of innate immunity genes in eastern India.
|OA=1
}}

{{PMID Auto
|PMID=18452612
|Title=MBL2 and hepatitis C virus infection among injection drug users.
|OA=1
}}

{{PMID Auto
|PMID=18633131
|Title=Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.
|OA=1
}}

{{PMID Auto
|PMID=20056178
|Title=Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}